Overview

A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials. The clinical trial is divided into two parts, including single and successive administration.
Phase:
Phase 1
Details
Lead Sponsor:
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
Dongfang Hospital Beijing University of Chinese Medicine
Treatments:
Bufanolides